{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:39:40Z","timestamp":1792629580245,"version":"4.5.0"},"reference-count":100,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>A potential complication of pharmacotherapy for a given patient is the possibility of various side effects of drugs, which are manifested in many ways and constitute iatrogenic causes of diseases. Among the systemic side effects of drugs, there are also those involving the urinary tract, although these are less reported in the literature. The use of numerous drugs\u2014especially of anticholinergics or drugs with anticholinergic potential, opioid analgesics, non-steroidal anti-inflammatory drugs, antidepressants, first-generation antipsychotics (classic neuroleptics) and selected cardiovascular drugs (beta-blockers, thiazides potassium-sparing diuretics, statins), as well as others\u2014may increase the risk of developing urological disorders, such as urinary retention or incontinence, urinary tract infections, urolithiasis, erectile dysfunction in men and retroperitoneal fibrosis. The purpose of this paper is to characterise the abovementioned drug-induced disorders of the lower urinary tract on the basis of a non-systematic literature review.<\/jats:p>","DOI":"10.3390\/ph16071031","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T01:52:35Z","timestamp":1689904355000},"page":"1031","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Lower Urinary Tract Disorders as Adverse Drug Reactions\u2014A Literature Review"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5049-0026","authenticated-orcid":false,"given":"Lukasz","family":"Dobrek","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, Wroclaw Medical University, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,20]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2023, April 29). Geneva 2002. Safety of Medicines. A Guide to Detecting and Reporting Adverse Drug Reactions. Available online: https:\/\/www.who.int\/publications\/i\/item\/WHO-EDM-QSM-2002-2."},{"key":"ref_2","unstructured":"U.S. Food and Drug Administration (2023, April 29). IND Application Reporting: Safety Reports, Available online: https:\/\/www.fda.gov\/drugs\/investigational-new-drug-ind-application\/ind-application-reporting-safety-reports."},{"key":"ref_3","unstructured":"Council for International Organizations of Medical Sciences (2023, April 30). Cumulative Glossary with a Focus on Pharmacovigilance. Version 2.0. Geneva, Switzerland. Available online: https:\/\/cioms.ch\/publications\/product\/cioms-cumulative-pharmacovigilance-glossary\/."},{"key":"ref_4","unstructured":"(2023, April 29). EudraVigilance\u2014European Database of Suspected Adverse Drug Reaction Reports. Available online: https:\/\/www.adrreports.eu\/en\/glossary.html."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: Definitions, diagnosis, and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"ref_6","unstructured":"Schatz, S.N., and Weber, R.J. (2015). Adverse drug reactions. PSAP CNS\/Pharm. Pract., 5\u201321. Available online: https:\/\/www.accp.com\/docs\/bookstore\/psap\/2015B2.SampleChapter.pdf."},{"key":"ref_7","first-page":"12","article-title":"Adverse drug reactions","volume":"42","author":"Smith","year":"2013","journal-title":"Aust Fam. Physician"},{"key":"ref_8","first-page":"1","article-title":"Adverse drug reaction","volume":"2","author":"Olawale","year":"2018","journal-title":"Cauc. J. Health Sci. Public Health"},{"key":"ref_9","first-page":"103","article-title":"Adverse drug reactions: A comprehensive review","volume":"8","author":"Kumar","year":"2018","journal-title":"J. Drug Deliv. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"481","DOI":"10.7861\/clinmedicine.16-5-481","article-title":"Adverse drug reactions","volume":"16","author":"Coleman","year":"2016","journal-title":"Clin. Med. (Lond.)"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Woo, S.D., Yoon, J., Doo, G.E., Park, Y., Lee, Y., Lee, S.H., Lee, Y.H., and Ye, Y.M. (2020). Common causes and characteristics of adverse drug reactions in older adults: A retrospective study. BMC Pharmacol. Toxicol., 21.","DOI":"10.1186\/s40360-020-00464-9"},{"key":"ref_12","first-page":"1781","article-title":"Adverse drug reactions: Types and treatment options","volume":"68","author":"Riedl","year":"2003","journal-title":"Am. Fam. Physician"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Khalil, H., and Huang, C. (2020). Adverse drug reactions in primary care: A scoping review. BMC Health Serv. Res., 20.","DOI":"10.1186\/s12913-019-4651-7"},{"key":"ref_14","unstructured":"(2000). Available online: https:\/\/cioms.ch\/publications\/product\/reporting-adverse-drug-reactions-definitions-of-terms-and-criteria-for-their-use\/."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/978-3-642-16499-6_8","article-title":"Neurophysiology of the lower urinary tract","volume":"202","author":"Beckel","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_16","unstructured":"Cortes, G.A., and Flores, J.L. (2023, April 30). Physiology, Urination, StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK562181\/."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s12035-018-1131-8","article-title":"The Role of the periaqueductal gray matter in lower urinary tract function","volume":"56","author":"Zare","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2165\/00002018-200831050-00002","article-title":"Drug-induced urinary retention: Incidence, management and prevention","volume":"31","author":"Verhamme","year":"2008","journal-title":"Drug Saf."},{"key":"ref_19","unstructured":"Rahman, M., Rahman, M., and Siddik, A.B. (2023). StatPearls, StatPearls Publishing. Available online: https:\/\/www.statpearls.com\/ArticleLibrary\/viewarticle\/27426#."},{"key":"ref_20","first-page":"119","article-title":"Overactive bladder\u2014Current definition and basic pathophysiology concepts","volume":"20","author":"Dobrek","year":"2011","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/bmj.308.6934.929","article-title":"New words for old: Lower urinary tract symptoms for \u201cprostatism\u201d","volume":"308","author":"Abrams","year":"1994","journal-title":"BMJ"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.eururo.2008.03.109","article-title":"Lower urinary tract symptoms revisited: A broader clinical perspective","volume":"54","author":"Chapple","year":"2008","journal-title":"Eur. Urol."},{"key":"ref_23","first-page":"137","article-title":"Postobstructive diuresis","volume":"61","author":"Halbgewachs","year":"2015","journal-title":"Can. Fam. Physician"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"102","DOI":"10.12688\/f1000research.7344.1","article-title":"The underactive bladder: Detection and diagnosis","volume":"5","author":"Osman","year":"2016","journal-title":"F1000Research"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"975","DOI":"10.23736\/S1973-9087.17.04992-9","article-title":"Diagnosis and clinical evaluation of neurogenic bladder","volume":"53","author":"Amarenco","year":"2017","journal-title":"Eur. J. Phys. Rehabil. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S186","DOI":"10.21037\/tau.2017.04.07","article-title":"The underactive bladder: Diagnosis and surgical treatment options","volume":"6","author":"Gani","year":"2017","journal-title":"Transl. Androl. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2165\/00002018-199819010-00004","article-title":"Drug-induced bladder and urinary disorders. Incidence, prevention and management","volume":"19","author":"Drake","year":"1998","journal-title":"Drug Saf."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/tre.581","article-title":"Adverse drug reactions and urological disease","volume":"8","author":"Baydal","year":"2017","journal-title":"Trends Urol. Men\u2019s Health"},{"key":"ref_29","first-page":"115","article-title":"Urinary incontinence\u2014From childhood onwards","volume":"61","year":"2022","journal-title":"Acta Clin. Croat."},{"key":"ref_30","first-page":"27","article-title":"Evaluation and management of female urinary incontinence","volume":"28","author":"Denisenko","year":"2021","journal-title":"Can. J. Urol."},{"key":"ref_31","first-page":"36","article-title":"Male urinary incontinence after prostate disease treatment","volume":"27","author":"Das","year":"2020","journal-title":"Can. J. Urol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2165\/00002512-200825070-00001","article-title":"Drug-induced urinary incontinence","volume":"25","author":"Tsakiris","year":"2008","journal-title":"Drugs Aging"},{"key":"ref_33","first-page":"24","article-title":"Drug-induced urinary incontinence","volume":"39","author":"Panesar","year":"2014","journal-title":"US Pharm."},{"key":"ref_34","first-page":"209","article-title":"Pharmacological management of urinary incontinence: Current and emerging treatment","volume":"13","author":"Gandi","year":"2021","journal-title":"Clin. Pharmacol."},{"key":"ref_35","first-page":"339","article-title":"Urinary Incontinence in women: Evaluation and management","volume":"100","author":"Hu","year":"2019","journal-title":"Am. Fam. Physician"},{"key":"ref_36","unstructured":"Bono, M.J., Leslie, S.W., and Reygaert, W.C. (2023, March 17). Urinary tract infection, StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470195\/."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrmicro3432","article-title":"Urinary tract infections: Epidemiology, mechanisms of infection and treatment options","volume":"13","author":"Walker","year":"2015","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jiac.2023.04.019","article-title":"Urinary tract infection in patients with lower urinary tract dysfunction","volume":"29","author":"Kamei","year":"2023","journal-title":"J. Infect. Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41585-020-0362-4","article-title":"Epidemiology, definition and treatment of complicated urinary tract infections","volume":"17","author":"Wagenlehner","year":"2020","journal-title":"Nat. Rev. Urol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Mancuso, G., Midiri, A., Gerace, E., Marra, M., Zummo, S., and Biondo, C. (2023). Urinary tract infections: The current scenario and future prospects. Pathogens, 12.","DOI":"10.3390\/pathogens12040623"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.36740\/WLek202107130","article-title":"Drug-related urinary tract infections","volume":"74","author":"Dobrek","year":"2021","journal-title":"Wiad. Lek."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3892\/etm.2021.10056","article-title":"Chemical hemorrhagic cystitis: Diagnostic and therapeutic pitfalls (Review)","volume":"21","author":"Petca","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.urology.2016.07.030","article-title":"Review of advances in uroprotective agents for cyclophosphamide- and ifosfamide-induced hemorrhagic cystitis","volume":"100","author":"Matz","year":"2017","journal-title":"Urology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"333","DOI":"10.17306\/J.AFS.0832","article-title":"Uroprotective mechanisms of natural products against cyclophosphamide-induced urinary bladder toxicity: A comprehensive review","volume":"19","author":"Sherif","year":"2020","journal-title":"Acta Sci. Pol. Technol. Aliment."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/bju.12291","article-title":"Chemical- and radiation-induced haemorrhagic cystitis: Current treatments and challenges","volume":"112","author":"Payne","year":"2013","journal-title":"BJU Int."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"592","DOI":"10.5604\/17322693.1009703","article-title":"Bladder urotoxicity pathophysiology induced by the oxazaphosphorine alkylating agents and its chemoprevention","volume":"66","author":"Dobrek","year":"2012","journal-title":"Postep. Hig. Med. Dosw. (Online)"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/nau.25148","article-title":"Current approaches for the treatment of ketamine-induced cystitis","volume":"42","author":"Zhou","year":"2023","journal-title":"Neurourol. Urodyn."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Chen, C.L., Wu, S.T., Cha, T.L., Sun, G.H., and Meng, E. (2022). Molecular pathophysiology and potential therapeutic strategies of ketamine-related cystitis. Biology (Basel), 11.","DOI":"10.3390\/biology11040502"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/iju.12841","article-title":"Possible pathophysiology of ketamine-related cystitis and associated treatment strategies","volume":"22","author":"Jhang","year":"2015","journal-title":"Int. J. Urol."},{"key":"ref_50","first-page":"S45","article-title":"Epidemiology of nephrolithiasis","volume":"13","author":"Ramello","year":"2000","journal-title":"J. Nephrol."},{"key":"ref_51","first-page":"30","article-title":"Review on uro-lithiasis pathophysiology and aesculapian discussion","volume":"8","author":"Jayaraman","year":"2018","journal-title":"IOSR J. Pharm."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.36740\/WLek202009226","article-title":"Kidney stone disease with special regard to drug-induced kidney stones\u2014A contemporary synopsis","volume":"73","author":"Dobrek","year":"2020","journal-title":"Wiad. Lek."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.pop.2020.08.005","article-title":"Nephrolithiasis","volume":"47","author":"Bishop","year":"2020","journal-title":"Prim. Care"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/0004563218781672","article-title":"Renal stones","volume":"56","author":"Viljoen","year":"2019","journal-title":"Ann. Clin. Biochem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3068365","DOI":"10.1155\/2018\/3068365","article-title":"Kidney stone disease: An update on current concepts","volume":"2018","author":"Alelign","year":"2018","journal-title":"Adv. Urol."},{"key":"ref_56","first-page":"14073","article-title":"Nephrolithiasis: An update on current concepts","volume":"6","author":"Begum","year":"2019","journal-title":"IAJPS"},{"key":"ref_57","unstructured":"(2023, March 17). European Associaton of Urology Guidelines. Urolithiasis. Available online: https:\/\/uroweb.org\/guidelines\/urolithiasis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cvsm.2008.09.004","article-title":"Drug-induced urolithiasis","volume":"39","author":"Osborne","year":"2008","journal-title":"Vet. Clin. Small Anim."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40272-019-00355-5","article-title":"Drug-induced urolithiasis in pediatric patients","volume":"21","author":"Sighinolfi","year":"2019","journal-title":"Paediatr. Drugs"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Dobrek, L. (2023). A synopsis of current theories on drug-induced nephrotoxicity. Life, 13.","DOI":"10.3390\/life13020325"},{"key":"ref_61","first-page":"227","article-title":"Drug-induced urinary calculi","volume":"5","author":"Matlaga","year":"2003","journal-title":"Rev. Urol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40265-017-0853-7","article-title":"Drug-induced kidney stones and crystalline nephropathy: Pathophysiology, prevention and treatment","volume":"78","author":"Daudon","year":"2018","journal-title":"Drugs"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/00003495-200464030-00003","article-title":"Drug-induced renal calculi: Epidemiology, prevention and management","volume":"64","author":"Daudon","year":"2004","journal-title":"Drugs"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.drudis.2019.01.012","article-title":"Adverse drug reactions on sexual functioning: A systematic overview","volume":"24","author":"Gordijn","year":"2019","journal-title":"Drug Discov. Today"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"42","DOI":"10.18773\/austprescr.2013.021","article-title":"Drug-induced sexual dysfunction in men and woman","volume":"36","author":"Conaglen","year":"2013","journal-title":"Aust. Prescr."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/postgradmedj-2017-135233","article-title":"Effect of prescription medications on erectile dysfunction","volume":"94","author":"Razdan","year":"2018","journal-title":"Postgrad. Med. J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1082-7579(98)00024-7","article-title":"Drug-induced sexual dysfunction","volume":"3","author":"Fecik","year":"1998","journal-title":"Med. Update Psychiatr."},{"key":"ref_68","unstructured":"Engelsgjerd, J.S., and LaGrange, C.A. (2023, March 18). Retroperitoneal Fibrosis, StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482409\/."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/iju.14218","article-title":"Current approach to diagnosis and management of retroperitoneal fibrosis","volume":"27","author":"Tanaka","year":"2020","journal-title":"Int. J. Urol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"256","DOI":"10.5114\/reum.2016.63667","article-title":"Retroperitoneal fibrosis\u2014The state-of-the-art","volume":"54","author":"Runowska","year":"2016","journal-title":"Reumatologia"},{"key":"ref_71","first-page":"1078","article-title":"Revisiting the retroperitoneal fibroses: Are there any significant news about their aetiopathogenesis and diagnostic approaches?","volume":"16","author":"Alberti","year":"2012","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_72","first-page":"187","article-title":"Drug-induced retroperitoneal fibrosis: Short aetiopathogenetic note, from the past times of ergot-derivatives large use to currently applied bio-pharmacology","volume":"36","author":"Alberti","year":"2015","journal-title":"G Chir."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/14740338.2020.1766022","article-title":"Drug-induced retroperitoneal fibrosis: A case\/non-case study in the French PharmacoVigilance Database","volume":"19","author":"Brasselet","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/nau.24695","article-title":"Urinary side effects of psychotropic drugs: A systematic review and metanalysis","volume":"40","author":"Trinchieri","year":"2021","journal-title":"Neurourol. Urodyn."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jpsychires.2021.10.026","article-title":"Urological adverse drug reactions of psychotropic medication in psychiatric inpatients\u2014A drug surveillance report from German-speaking countries","volume":"144","author":"Winkler","year":"2021","journal-title":"J. Psychiatr. Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"22cr03254","DOI":"10.4088\/PCC.22cr03254","article-title":"Sertraline-induced urinary retention reversed by mirtazapine in an adolescent","volume":"24","author":"Jiang","year":"2022","journal-title":"Prim. Care Companion CNS Disord."},{"key":"ref_77","first-page":"117","article-title":"Switching to fluoxetine in a case of sertraline-induced urinary incontinence: A case report","volume":"26","author":"Ozdemir","year":"2023","journal-title":"D\u00fc\u015f\u00fcnen Adam J. Psychiatry Neurol. Sci."},{"key":"ref_78","first-page":"117","article-title":"Dose-dependent urinary incontinence with sertraline use in obsessive-compulsive disorder","volume":"51","author":"Pease","year":"2021","journal-title":"Psychopharmacol. Bull."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/psb.187","article-title":"Amitryptyline in BPH: Increased risk of PVR and urinary retention","volume":"19","author":"Howard","year":"2008","journal-title":"Prescriber"},{"key":"ref_80","first-page":"60","article-title":"Tricyclic antidepressant-induced acute urine retention in a young woman with postpartum depression--case report","volume":"34","author":"Stamatiou","year":"2007","journal-title":"Clin. Exp. Obstet. Gynecol."},{"key":"ref_81","first-page":"6157548","article-title":"Expanding our understanding of atypical antipsychotics: Acute urinary retention secondary to olanzapine","volume":"2020","author":"Mirzakhani","year":"2020","journal-title":"Case Rep. Psychiatry"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/02537176221111581","article-title":"Olanzapine-associated chronic urinary retention and ciliochoroidal effusion: Rare adverse effects of a commonly prescribed antipsychotic","volume":"45","author":"Purohith","year":"2023","journal-title":"Indian J. Psychol. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.juro.2012.04.011","article-title":"The possible role of opiates in women with chronic urinary retention: Observations from a prospective clinical study","volume":"188","author":"Panicker","year":"2012","journal-title":"J. Urol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"109.e1","DOI":"10.1016\/j.ajem.2013.08.022","article-title":"Acute urinary retention secondary to buprenorphine administration","volume":"32","author":"Edwards","year":"2014","journal-title":"Am. J. Emerg. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1067\/mcp.2002.129318","article-title":"Benzodiazepines and the risk of urinary incontinence in frail older persons living in the community","volume":"72","author":"Landi","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1080\/24750573.2017.1400936","article-title":"Acute urinary retention after alprazolam use: A case report","volume":"28","author":"Aykut","year":"2018","journal-title":"Psychiatry Clin. Psychopharmacol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.juro.2012.02.2575","article-title":"Associations of commonly used medications with urinary incontinence in a community based sample","volume":"188","author":"Hall","year":"2012","journal-title":"J. Urol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Elhebir, E.S., Hughes, J.D., and Hilmi, S.C. (2013). Calcium antagonists use and its association with lower urinary tract symptoms: A cross-sectional study. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0066708"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"4269875","DOI":"10.1155\/2017\/4269875","article-title":"Effect of calcium channel blockers on lower urinary tract symptoms: A systematic review","volume":"2017","author":"Salman","year":"2017","journal-title":"Biomed. Res. Int."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Uitrakul, S., Aksonnam, K., Srivichai, P., Wicheannarat, S., and Incomenoy, S. (2022). The incidence and risk factors of urinary tract infection in patients with type 2 diabetes mellitus using SGLT2 inhibitors: A real-world observational study. Medicines, 9.","DOI":"10.3390\/medicines9120059"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1590\/1806-9282.65.2.246","article-title":"Use of sodium-glucose cotransporter-2 inhibitors and urinary tract infections in type 2 diabetes patients: A systematic review","volume":"65","author":"Figueiredo","year":"2019","journal-title":"Rev. Assoc. Med. Bras."},{"key":"ref_92","first-page":"e21720","article-title":"Frequency of urinary tract infections in type 2 diabetic patients taking dapagliflozin","volume":"14","author":"Khan","year":"2022","journal-title":"Cureus"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1681\/ASN.2017111213","article-title":"Oral antibiotic exposure and kidney stone disease","volume":"29","author":"Tasian","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_94","first-page":"177","article-title":"Drug-induced erectile dysfunction: Two interesting cases","volume":"12","author":"Samajdar","year":"2021","journal-title":"J. Pharmacol. Pharmacother."},{"key":"ref_95","first-page":"e35357","article-title":"Risperidone-induced sexual dysfunction case report","volume":"15","author":"Cichon","year":"2023","journal-title":"Cureus"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1002\/ccr3.3946","article-title":"A community pharmacist\u2019s intervention in antipsychotic drug-induced sexual dysfunction in a patient with schizophrenia","volume":"9","author":"Maehara","year":"2021","journal-title":"Clin. Case Rep."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0022-5347(17)41059-7","article-title":"Hydralazine, hydrochlorothiazide and ampicillin associated with retroperitoneal fibrosis: Case report","volume":"141","author":"Waters","year":"1989","journal-title":"J. Urol."},{"key":"ref_98","first-page":"389","article-title":"Retroperitoneal fibrosis caused by pergolide in a patient with Parkinson\u2019s disease","volume":"62","author":"Bilici","year":"2004","journal-title":"Neth. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1056\/NEJM196602172740701","article-title":"Fibrotic disorders associated with methysergide therapy for headache","volume":"274","author":"Graham","year":"1966","journal-title":"N. Engl. J. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.2482\/haigan.62.1044","article-title":"Two cases of retroperitoneal fibrosis during anti-programmed cell death 1 antibody treatment","volume":"62","author":"Fujiu","year":"2022","journal-title":"JJLC"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/7\/1031\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:15:43Z","timestamp":1760127343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/7\/1031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,20]]},"references-count":100,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["ph16071031"],"URL":"https:\/\/doi.org\/10.3390\/ph16071031","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,20]]}}}